Introduction
============

Anthranilate (oAB, *ortho*-aminobenzoate) is an aromatic acid used as a platform chemical for the production of food ingredients ([@B43]), dyes, perfumes ([@B57]), crop protection compounds ([@B3]; [@B59]; [@B12]), pharmaceutical compounds ([@B6]; [@B45]; [@B24]; [@B20]; [@B35]; [@B52]), and plastics such as nylon ([@B47]). It is currently produced in energy intensive chemical processes from petroleum-based precursors, like phthalamic acid ([@B31]; [@B9]). Furthermore, the production of the precursors and the production of oAB accumulate toxic byproducts, such as hypochlorite which is used with molar equivalency to oAB ([@B9]). Thus, there is a strong motivation to find alternative routes to produce platform chemicals, such as oAB, in green production processes from renewable resources in an environmental friendly way. In addition, the development and application of green production processes is accelerated by an environmental and political interest to be less dependent on fossil resources.

Biocatalysis using living microbes as catalysts is a well-established alternative for the production of chemicals. The aromatic biosynthesis pathway and the derived compounds of the aromatic acids, such as oAB, have been intensively studied in the last decades ([@B11]; [@B28]; [@B32]; [@B34]; [@B41]). Microbial production of oAB with engineered *Escherichia coli* strains was reported by [@B7] followed by further publications on oAB-derived compounds such as catechol and muconic acid ([@B47]; [@B4]; [@B8]; [@B29]). To enable oAB production in *E. coli*, [@B7], [@B8]) inserted a point mutation in the oAB phosphoribosyl transferase domain (*trpD*), whereas [@B47] used the Keio collection deletion strain *E. coli* BW25113 Δ*trp::kan* to prevent the conversion of oAB to tryptophan. Additional targets to increase the production of oAB in *E. coli*, for example the overexpression of feedback insensitive variants of the 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) synthase and the anthranilate synthase unit (*trpE^*S40F*^G*) were investigated. A maximum titer of 14 g L^-1^ oAB was reported growing the engineered strains in complex medium containing 30 g L^-1^ yeast extract ([@B7]).

Here, we present the first attempt of microbial production of oAB from glucose as sole carbon source with an engineered *P seudomonas putida* KT2440 strain. Due to its versatile metabolism and low nutritional requirements *P. putida* is an efficient production strain for various industrial relevant products ([@B48]). In addition its high biomass yield, high growth rate, and low maintenance demand fulfill the rigorous demands of industrial biotechnology ([@B42]). A broad portfolio of *P. putida* biocatalysts for bulk chemicals such as phenol ([@B54]), *p*-hydroxystyrene ([@B51]), *p***-**hydroxybenzoate ([@B50]), rhamnolipids ([@B58]), polyhydroxyalkanoates (PHA; [@B53]), and (S)-styrene oxide ([@B10]) demonstrate the great potential of this species as a flexible cell factory for the production of chemicals in industrial biotechnology. In addition, *P. putida* strains have the capability to withstand various chemical stresses such as a second phase of toluene, octanol, or styrene ([@B25]; [@B17]; [@B10]), as well as oxidative stress ([@B13]) and reduced water activity ([@B22]), and thus providing a promising and versatile chassis for the production of toxic compounds such as oAB.

To ensure industrially relevant oAB production conditions a full, markerless deletion of *trpDC* was performed in *P. putida*, facilitated by the fact that in contrast to *E. coli* the *trpEG* and *trpDC* genes are encoded by separate open reading frames. Additionally the production of oAB was realized on glucose as sole carbon source, avoiding the addition of high amounts of complex media components such as yeast extract. A maximum titer of 1.54 ± 0.3 g L^-1^ (11.23 mM) oAB was obtained with the best performing engineered *P. putida* KT2440 strain (*P. putida* Δ*trpDC* pSEVA234\_*aroG^*D146N*^\_trpE^*S40F*^G*) in tryptophan-limited fed-batch fermentations with glucose as sole carbon source.

Materials and Methods {#s1}
=====================

Strains and Plasmids
--------------------

The deletion of *trpDC* and *pheA* were performed by a clean and markerless deletion method described by [@B36] resulting in two knock out strains *P. putida KT2440 trpDC* and *P. putida* KT2440 *trpDC pheA*. To obtain the knockout vectors pEMG_Δ*trpDC* and pEMG_Δ*pheA* were obtained via a standard restriction and ligation approach and were transformed into chemical competent *E. coli* DH5α (according to [@B14]) via electroporation. The 800-bp flanks upstream (TS1) and downstream (TS2) of the gene of interest (*trpDC* and *pheA*) were amplified by PCR using a Pfu polymerase (New England Biolabs) with the primers listed in **Table [1](#T1){ref-type="table"}**.

###### 

Primer sequences.

  Name             DNA sequence                                    *T*~m~ (°C)
  ---------------- ----------------------------------------------- -------------
  **TS1 ΔtrpDC**                                                   
  JK034f           agggataacagggtaatctgaatTCGTCAGCAAACTCTTGATG     61.6
  JK035r           tttgactcgagGTTCGATCCTTAACGGCG                   61.6
  **TS2 ΔtrpDC**                                                   
  JK036f           aggatcgaacctcgagTCAAATGAAGCCGGCGTT              66.1
  JK037r           cctgcaggtcgactctagaggatccTCGAACCAAGGTGCTACCG    66.1
  **TS1 ΔpheA**                                                    
  JK038f           attcgagctcggtacccggggatccACTACATCGAAACCGGCATC   61.8
  JK039r           ctgaactcgagTCAGCCATGCTCCTTCTC                   61.8
  **TS2 ΔpheA**                                                    
  JK040f           gcatggctgactcgagTTCAGGGGCCTTGGGGCT              70.2
  JK041r           tagaagcttgcatgcctgcaggCAGTGAGTCGACCAGGCCAAAG    70.2

TS1 and TS2 were fused in a SOEing-PCR using Pfu polymerase according to [@B27]. The backbone (pEMG) and the fused SOEing-PCR fragment were digested with *BamHI* and *EcoRI* for the deletion of *trpDC* and with *BamHI* and *SbfI* for the deletion of *pheA*. The digested backbones, TS1, and TS2 were purified (High Pure PCR Product Purification Kit, Roche), ligated with a T4 DNA ligase (Thermo Fisher Scientific) and transformed into chemical competent *E. coli* DH5α (according to [@B14]) via electroporation. Constructs were verified by restriction analysis and sequencing, resulting in pEMG_Δ*trpDC* and pEMG_Δ*pheA*. Genome integration of the knockout constructs into the *P. putida* strains was performed via tri**-**parental mating according to [@B16] using *E. coli* HB101 pRK2013 as the helper strain and facilitated as described in [@B61] where the three mating strains were streaked one above the other on a LB plate. The resulting strains were transformed with the plasmid expressing the I*Sce*-I endonuclease (pSW-I; according to [@B14]). Induction with 3-methylbenzoate was omitted due to the leaky expression of the I*Sce*-I nuclease. Successful construction of the knockout strains was verified via restriction, PCR and Sanger sequencing.

The feedback insensitive overexpression constructs were obtained via a standard restriction and ligation approach as described above using *BamHI* and *EcoRI* for *aroG^*D146N*^* and *BamHI* for *trpE^*S40F*^G*. pSEVA234 ([@B46]), which contains an IPTG inducible lacI^Q^-P~trc~ expression system, was used as backbone. The genes *aroG^D146N^* ([@B30]; [@B1]) and *trpE^*S40F*^G* ([@B33]) were synthesized at Eurofins Genomics. A summary of the used and constructed plasmids and of the engineered strains is shown in **Table [2](#T2){ref-type="table"}**. All primers were purchased at Eurofins Genomics and all restriction enzymes at Thermo Fisher Scientific.

###### 

Summary of plasmids and strains used in this study.

                                                                                   Description                                                                                  Reference
  -------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ---------------------------
  **Plasmids**                                                                                                                                                                  
  pEMG                                                                             Km^R^, *ori*R6K, *lacZ*a with two flanking I-*Sce*I sites                                    [@B36]
  pSEVA234                                                                         Km^R^, *oriBBR1*, *lacI^q^*-*Ptrc*                                                           [@B46]
  pSW-I                                                                            Ap^R^, *ori*RK2, *xylS*, *Pm*→*I-Sce*I                                                       [@B36]
  pRK2013                                                                          Km^R^, *ori*RK2, *ori*ColE1                                                                  [@B18]
  pEMG_Δ*trpDC*                                                                    *trpDC* deletion plasmid                                                                     This work
  pEMG_Δ*pheA*                                                                     *pheA* deletion plasmid                                                                      This work
  pSEVA234\_*trpE^*S40F*^G*                                                        *trpE^*S40F*^G* expression plasmid                                                           This work
  pSEVA234\_*aroG^**D146N**^*                                                      *aroG^*D146N*^* expression plasmid                                                           This work
  pSEVA234\_*aroG^*D146N*^*\_*trpE^*S40F*^G*                                       *aroG^*D146N*^*-*trpE^*S40F*^G* expression plasmid                                           This work
  **Strain**                                                                                                                                                                    
  *Psuedomonas putida* KT2440                                                      Wild-type strain derived of *P. putida* mt-2 cured of the pWW0 plasmid                       [@B5]
  *Escherichia coli* DH5α                                                          *supE44*, D*lacU169 (*f*80 lacZ*D*M15), hsdR17 (rk-mk*+*), recA1, endA1, thi1, gyrA, relA*   [@B23]
  *E. coli* DH5α aaapir                                                            aaapir phage lysogen of DH5α                                                                 De Lorenzo Lab collection
  *E. coli* HB101 pRK2013                                                          Sm^R^, *hsdR-M*+, *pro, leu, thi, recA*, Km^R^, *ori*RK2, *ori*ColE1                         [@B18]
  *E. coli* DH5α aaapir pEMG                                                       Plasmid carrier strain                                                                       [@B36]
  *E. coli* DH5α aaapir pSW-I                                                      Plasmid carrier strain                                                                       [@B36]
  *E. coli* DH5α aaapir pEMG_Δ*trpDC*                                              Plasmid carrier strain                                                                       This work
  *E. coli* DH5α aaapir pEMG_Δ*pheA*                                               Plasmid carrier strain                                                                       This work
  *E. coli* DH5α pSEVA234\_*trpE^*S40F*^G*                                         Plasmid carrier strain                                                                       This work
  *E. coli* DH5α pSEVA234\_*aroG^*D146N*^*                                         Plasmid carrier strain                                                                       This work
  *E. coli* DH5α pSEVA234\_*aroG^*D146N*^*\_*trpE^*S40F*^G*                        Plasmid carrier strain                                                                       This work
  *P. putida* KT2440 pSEVA234\_*trpE^*S40F*^G*                                     oAB production strain                                                                        This work
  *P. putida* KT2440 pSEVA234\_*aroG^*D146N*^*                                     oAB production strain                                                                        This work
  *P. putida* KT2440 pSEVA234\_*aroG^*D146N*^*\_*trpE^*S40F*^G*                    oAB production strain                                                                        This work
  *P. putida* KT2440 Δ*trpDC*                                                      oAB production strain                                                                        This work
  *P. putida* KT2440 Δ*trpDC* pSEVA234\_*trpE^*S40F*^G*                            oAB production strain                                                                        This work
  *P. putida* KT2440 Δ*trpDC* pSEVA234\_*aroG^*D146N*^*                            oAB production strain                                                                        This work
  *P. putida* KT2440 Δ*trpDC* pSEVA234\_*aroG^*D146N*^*\_*trpE^*S40F*^G*           oAB production strain                                                                        This work
  *P. putida* KT2440 Δ*trpDC* Δ*pheA*                                              oAB production strain                                                                        This work
  *P. putida* KT2440 Δ*trpDC* Δ*pheA* pSEVA234\_*trpE^*S40F*^G*                    oAB production strain                                                                        This work
  *P. putida* KT2440 Δ*trpDC* Δ*pheA* pSEVA234\_*aroG^*D146N*^*                    oAB production strain                                                                        This work
  *P. putida* KT2440 Δ*trpDC* Δ*pheA* pSEVA234\_*aroG^*D146N*^*\_*trpE^*S40F*^G*   oAB production strain                                                                        This work

Cultivation Conditions
----------------------

For cloning and maintenance processes, *E. coli* strains and *P. putida* strains were cultivated at 37 and 30°C, respectively, in LB medium supplemented with or without kanamycin (50 mg L^-1^) or ampicillin (100 mg L^-1^ for *E. coli* and 500 mg L^-1^ for *P. putida*), and/or with 1.5% (w/v) agar as needed.

Auxotrophies (tryptophan and phenylalanine) of the gene deletion mutants were verified on solid mineral medium plates ([@B54]) with 1.5% (w/v) agar, 20 mM glucose with and without 1 mM tryptophan, and/or 1 mM phenylalanine supplementation. Alternatively 1 mM phenylpyruvate was used instead of phenylalanine.

Batch-wise oAB production was performed in 500 mL shake flasks at 30°C and 200 rpm in 50 mL mineral medium as described in [@B54] with 20 mM glucose (unless stated differently), 50 mg L^-1^ kanamycin, and 1 mM IPTG, supplemented with either 0.1 or 0.05 mM tryptophan and 1 mM phenlypyruvate for the Δ*pheA* strains. Two additional 20 mM glucose pulses were added after 10 and 24 h unless stated differently.

Tryptophan-limited fed-batch conditions were realized in controlled bioreactors (BioFlo 110 or BioFlo 115, Eppendorf / New Brunswick Scientific) with a starting volume of 400 mL. The initial fermentation medium consisted of mineral medium with 50 mM glucose, a twofold phosphate buffer concentration, a threefold (NH~4~)~2~SO~4~ concentration, a onefold trace element solution, 1 mM IPTG, 50 mM kanamycin, and 0.1 mM tryptophan. After the initial batch phase, the feed was switched on at a rate of 2 mL h^-1^ consisting of a mixed solution of 1 M glucose and 0.5 mM (glucose to tryptophan molar ratio of 2,000:1) or 1 mM (glucose to tryptophan molar ratio of 1,000:1) tryptophan. To compensate for the increasing biomass concentrations the 1 mM tryptophan feed was increased to 6 mL h^-1^. The fermentations were performed at 30°C, with 500--1,200 rpm agitation (dO~2~ regulated agitation cascade with a lower limit of 35%), with 1 vvm headspace aeration of compressed air. The pH was regulated to pH = 7 with 2 M KOH and 4 M H~2~SO~4~.

Analytics
---------

The biomass concentration was measured with a spectrophotometer (Ultrospec 10, GE Healthcare Life Sciences). In this device the OD~600~ correlates to cell dry weight (CDW): 1 OD~600~ = 0.505 g~CDW~ L^-1^. The samples taken during cultivation were centrifuged at 13,300 rpm for 3 min and stored at -20°C for further analysis. To follow the consumption of the glucose and derivatives (gluconate and 2**-**ketogluconate) by the *P. putida* KT2440 strains, a Beckman HPLC equipped with an organic acid resin column (polystyrol**-**divinylbenzol copolymer, PS-DVB: 300 × 8.0 mm, CS-Chromatographie) was used with 5 mM H~2~SO~4~ as eluent at a flow of 0.8 mL h^-1^ for 11 min at 75°C. Detection was realized with an UV detector at a wavelength of 210 nm and a RI detector. The oAB production was analyzed with a reverse phase column (LiChrosorb 100 RP-18, 250 × 4 mm, Merck), at a flow of 1.2 mL h^-1^ \[pump gradient of H~2~O + 0.1% TFA (pump A) and of MeOH (pump B): 0--2 min 90% A, 2--12 min gradient 0--90% A, 12--14 min 0% A, 14--15 min gradient 0--90% A, and 15--16 min 90% A\] at 30°C. Detection was realized with an UV detector at a wavelength of 257 nm and a RI detector.

Results and Discussion
======================

Metabolic Engineering of oAB Production Strains
-----------------------------------------------

In order to establish oAB production in *P. putida*, the *trpDC* and *pheA* genes were knocked out using the I-*Sce*I-based pEMG system ([@B36]). Disruption of the *trpDC* genes, which encode an anthranilate phosphoribosyltransferase (TrpD) and an indole-3-glycerol phosphate synthase (TrpC), leads to a tryptophan auxotrophy and enables the accumulation of oAB (**Figure [1](#F1){ref-type="fig"}**). Disruption of the *pheA* gene, which encodes a bifunctional chorismate mutase/prephenate dehydratase enzyme responsible for the first two steps of the synthesis of phenylalanine and tyrosine, possibly increases the metabolic flux toward oAB by reducing the drain on its primary precursor chorismate ([@B60]). Contrary to other established production hosts, the *pheA* deletion only requires phenylalanine to complement growth since *P. putida* can convert phenylalanine to tyrosine ([@B38]). The corresponding auxotrophies were verified on mineral medium plates (**Table [3](#T3){ref-type="table"}**).

![**Schematic oAB production pathway including the metabolic engineering targets investigated in this study (overexpression of *aroG^*D146N*^trpE^*S40F*^G* and deletion of *trpDC* and *pheA)*.** PEP, phosphoenolpyruvate; E4P, erythrose-4-phosphate; DAHP, 3-Deoxy-D-arabinoheptulosonate-7-phosphate.](fmicb-06-01310-g001){#F1}

###### 

Auxotrophy supplementation of *P. putida* KT2440 Δ*trpDC* and Δ*pheA* knockouts.

  Name                                  Supplementation^a^   Growth
  ------------------------------------- -------------------- --------
  *P. putida* KT2440                    None                 \+
                                        trp                  \+
                                        phe                  \+
                                        trp + phe            \+
  *P. putida* KT2440 Δ*trpDC*           None                 \-
                                        Trp                  \+
  *P. putida* KT2440 Δ*trpDC* Δ*pheA*   None                 \-
                                        Trp                  \-
                                        trp + phe            \+
                                        trp + pp             \+

a

Mineral medium plates with 20 mM glucose supplemented with 1 mM tryptophan (trp), phenylalanine (phe), or phenylpyruvate (pp)

.

In the knockout process, the deletion of *pheA* could only be obtained by supplementation with phenylpyruvate. The final step of the knockout procedure (induction of the double strand break) should theoretically yield a one-to-one ratio of wildtype to knockout allele. However, selection on LB- or LB medium with phenylalanine resulted in the wildtype allele only, even after testing \>1,000 colonies either by PCR or by screening for phenylalanine auxotrophy. This may be attributed to the ability of *P. putida* to degrade phenylalanine and tyrosine. Possibly, supplementation with phenylpyruvate instead of phenylalanine reduced the induction of genes encoding the phenylalanine and tyrosine catabolic pathway ([@B2]), facilitating the successful isolation of the knockout strain. The final *pheA* knockout auxotroph could be complemented with phenylalanine in mineral medium. However, in this case a severe negative effect on the fitness of the mutant caused by the deletion of *pheA* was observed. Therefore, all subsequent Δ*pheA* complementation were done with phenylpyruvate.

To further optimize the production of oAB in *P. putida*, feedback insensitive pSEVA234-based ([@B46]) overexpression constructs for *trpE^*S40F*^G* and *aroG^*D146N*^*, or both genes in one operon structure, were transformed to the respective mutants under the IPTG-inducible LacI^Q^-P~trc~ system. These genes encode feedback insensitive variants of anthranilate synthase and 3-deoxy-D-arabino-heptulosonate-7-phosphate (DHAP) synthase, respectively, and are known to enhance oAB production in *E. coli* ([@B7], [@B8]; [@B47]). **Figure [1](#F1){ref-type="fig"}** shows the exemplarily oAB production pathway and gives on overview over the metabolic engineering targets investigated in this study.

Evaluation of oAB Production Strains in Shake Flasks
----------------------------------------------------

The *P. putida* strains engineered for the production of oAB (listed in **Table [2](#T2){ref-type="table"}**) were initially assessed in shake flasks (**Figures [2A,B](#F2){ref-type="fig"}**) and under slightly optimized production conditions a maximum titer of 0.25 ± 0.004 g L^-1^ (1.83 mM) oAB with glucose as sole carbon source was achieved (**Figure [3](#F3){ref-type="fig"}**). The three Δ*trpDC* strains bearing either *trpE^*S40F*^G*, *aroG^*D146N*^* or both, have shown no significant differences in maximal oAB titers, although the onset of production was earlier in the *P. putida* KT2440 Δ*trpDC* pSEVA234\_*aroG^*D146N*^*\_*trpE^*S40F*^G*. Interestingly, oAB production was also observed with *P. putida* KT2440 pSEVA234\_*aroG^*D146N*^*\_*trpE^*S40F*^G* (without *trpDC* deletion) while no tryptophan was secreted, although the maximal titer was lower than that of the Δ*trpDC* strains. This can be explained by the transcriptional repression of *trp* genes by tryptophan through the TrpR repressor ([@B37]; [@B55]). Likely, an increase of intracellular tryptophan caused repression of the native *trp* genes, leading to anthranilate accumulation due to the heterologous expression of *trpE^*S40F*^G*.

![**oAB production profiles of various *P. putida* KT2440 strains in shake flasks.** Biomass growth **(A)** and oAB production **(B)** of the following *Pseudomonas putida* KT2440 strains in an initial screening experiment: ![](fmicb-06-01310-i001.jpg), Δ*trpDC* pSEVA234\_*trpE^*S40F*^G*; ![](fmicb-06-01310-i002.jpg), Δ*trpDC* pSEVA234\_*aroG^*D146N*^*; ![](fmicb-06-01310-i003.jpg), Δ*trpDC* pSEVA234\_*aroG^*D146N*^\_trpE^*S40F*^G*; ![](fmicb-06-01310-i004.jpg), Δ*trpDC* Δ*pheA* pSEVA234\_*trpE^*S40F*^G*; ![](fmicb-06-01310-i005.jpg), Δ*trpDC* Δ*pheA* pSEVA234\_*aroG^*D146N*^*; ![](fmicb-06-01310-i006.jpg), Δ*trpDC* Δ*pheA* pSEVA234\_*aroG^*D146N*^\_trpE^*S40F*^G*; ![](fmicb-06-01310-i007.jpg), pSEVA234\_*aroG^*D146N*^\_trpE^*S40F*^G*. All cultures were performed in mineral medium with 20 mM initial glucose concentration and addition of tryptophan and/or phenylpyruvate as described above. The arrows indicate the addition of glucose to a concentration of 20 mM.](fmicb-06-01310-g002){#F2}

![**Detailed profiles of ![](fmicb-06-01310-i008.jpg), cell dry weight; ![](fmicb-06-01310-i001.jpg), oAB; ![](fmicb-06-01310-i009.jpg), tryptophan (trp); ![](fmicb-06-01310-i010.jpg), dehydroshikimate (DHS) concentrations of the best selected strain *P.putida* KT2440 Δ*trpDC* pSEVA234\_*trpE^*S40F*^G* generated under slightly optimized production conditions.** All cultures were performed in mineral medium with 20 mM initial glucose concentration and addition of tryptophan and/or phenylpyruvate as described above. The arrows indicate the addition of glucose to a concentration of 20 mM.](fmicb-06-01310-g003){#F3}

A strong connection was observed between tryptophan limitation and oAB production. When supplementing the auxotrophic strains with tryptophan the oAB production was induced only upon depletion of the added tryptophan. Strains expressing both *aroG^*D146N*^* and *trpE^*S40F*^G* produced oAB at earlier time points compared to strains with only one of the feedback insensitive genes, indicating somewhat alleviated feedback insensitivity to tryptophan (**Figure [2](#F2){ref-type="fig"}**). With the non-auxotrophic *P. putida* pSEVA234\_*aroG^*D146N*^*\_*trpE^*S40F*^G*, where a supplementation with tryptophan was not required, oAB titers were significantly higher at earlier time points, indicating no inhibition by tryptophan. However, the final oAB titers were 34% lower compared to the *P. putida* Δ*trpDC* strains, indicating a positive effect of the deletion of *trpDC*.

As indicated above, a clear negative effect of the deletion of *pheA* on the growth behavior was observed. Whereas *P. putida* KT2440 pSEVA234\_*trpE^*S40F*^G* and *P. putida* KT2440 Δ*trpDC* pSEVA234\_*trpE^*S40F*^G* were able to grow up to 3.6 g L^-1^ CDW and 2.4 g L^-1^ CDW, respectively; *P.putida* KT2440 Δ*trpDC* Δ*pheA* pSEVA234\_*trpE^*S40F*^G* only reached a maximal CDW concentration of 1.4 g L^-1^ after 10 hours when supplemented with 1 mM phenylpyruvate. Further addition of glucose and/or tryptophan could neither initiate growth to higher CDW concentrations, nor did it improve oAB production. Normal growth was only fully rescued when supplementing high amounts of phenylpyruvate (≥5 mM) which would make the overall process highly uneconomical. Additionally, final oAB titers were still 49% lower than with the Δ*trpDC* strains, indicating a negative effect of the *pheA* deletion for the production of oAB in this organism. Thus, the most promising strain engineered for the production of oAB is *P. putida* Δ*trpDC* pSEVA234\_*aroG^*D146N*^*\_*trpE^*S40F*^G* as it reached high titers of oAB and showed reduced sensitivity to tryptophan.

Dehydroshikimate, a metabolic intermediate of the shikimate pathway and thus a precursor of oAB, accumulated as a by-product in all strains engineered for oAB production in shake flasks, indicating shikimate dehydrogenase as a likely bottleneck (**Figure [3](#F3){ref-type="fig"}**). This hypothesis is also supported by the transcriptome data sets of [@B56] and [@B49] showing upregulated 3-dehydroquinate and dehydroshikimate genes in the analyzed phenol and *p*-hydroxybenzoate production strains obtained by a fluoro-analog mutant screening.

Production of oAB in Controlled Bioreactors
-------------------------------------------

The potential of *P. putida* Δ*trpDC* pSEVA234\_*aroG^*D146N*^*\_*trpE^*S40F*^G* to produce oAB was further assessed in tryptophan-limited fed batch cultures to circumvent the observed inhibition by tryptophan and maximize final oAB titers. A glucose-to-tryptophan molar ratio of 400:1 was estimated for biomass growth alone based on the initial shake flask experiments. Therefore, two different feeding approaches with a molar ratio of glucose to tryptophan of 1,000:1 and 2,000:1 were used to ensure a tryptophan limitation without excessive accumulation of glucose or its derivatives. Under these conditions a maximal titer of 1.54 ± 0.3 g L^-1^ oAB was reached from glucose as sole carbon source using the 2,000:1 feed (**Figure [4](#F4){ref-type="fig"}**). The higher ratio of glucose to tryptophan led to a more severe growth limitation, with CDW increasing only marginally during the production of oAB. In contrast, the 1,000:1 feed enabled more biomass growth at the cost of oAB production, leading to a final product titer of 1.0 ± 0.07 g L^-1^. The product per substrate yield (based on consumed carbon source) for both conditions is relatively similar at 3.6 ± 0.5% (g/g) for the 1,000:1 feed and 3.5 ± 0.5% (g/g) for the 2,000:1 feed. oAB levels increased fairly linearly until the production stopped abruptly. Since the level of oAB produced is well below growth-inhibiting concentrations for *P. putida* (data not shown), oAB production is most likely stopped due to product inhibition, a known phenomenon for the production of aromatics ([@B21]; [@B55]; [@B44]). This product inhibition likely takes place at the level of the anthranilate synthase. Indeed, the anthranilate synthase complex of other organisms is already inhibited by oAB concentrations in the micromolar range ([@B15]; [@B26]; [@B19]). The oAB titers obtained with *P. putida* KT2440 in this study are about 10-fold lower than those achieved by [@B7]. The difference can most likely be attributed to the supplementation of 30 g/L yeast extract by these researchers, which can provide oAB precursors and increases the general stress tolerance of microorganisms. This apparent positive effect of yeast extract on oAB production should be further investigated in order to elucidate the responsible components.

![**Tryptophan-limited fed-batch cultures of *P. putida* KT2440 Δ*trpDC* pSEVA234\_*aroG^*D146N*^\_trpE^*S40F*^G* in controlled bioreactors with different feeding approaches. (A)** Feed molar ratio of glucose to tryptophan 1,000:1. **(B)** Feed molar ratio of glucose-to-tryptophan 2,000:1. ![](fmicb-06-01310-i011.jpg), cell dry weight; ![](fmicb-06-01310-i001.jpg), oAB concentration. The arrows indicate the start of the feed after the initial batch phase.](fmicb-06-01310-g004){#F4}

In the initial batch phase, the 50 mM glucose were entirely consumed for the production of biomass. Tryptophan limiting conditions were confirmed by HPLC analysis throughout the fermentation (\<0.1 mM). Carbon source, either as glucose or as gluconate and 2-ketogluconate, were constantly present during the feed phase at total concentrations between 0.4 and 8.6 g L^-1^. In some fermenters, a prolonged incubation led to a decrease of oAB concentrations over time. Possibly, polymerization of oAB and/or its conversion products occurred.

Conclusion
==========

Microbial production of oAB under industrial relevant conditions from glucose as sole carbon source was achieved in *P. putida* KT2440 via the biosynthesis pathway of aromatic amino acids. A strong connection between a tryptophan limitation and oAB production was observed even with strains bearing feedback insensitive overexpression constructs of *aroG^*D146N*^* and *trpE^*S40F*^G*. Under tryptophan limiting fed-batch conditions, a maximum titer of 1.54 ± 0.3 g L^-1^ oAB was achieved with *P. putida* KT2440 Δ*trpDC* pSEVA234\_*aroG^*D146N*^*\_*trpE^*S40F*^G*. This final achieved concentration is in the same range as other aromatics produced by *P. putida* strains ([@B39], [@B40]; [@B50]); although the titer is lower than that of previously published works with *E. coli* ([@B7]). However, the supplementation with yeast extract was avoided and oAB was only produced from glucose. In addition, to ensure long term strain stability, one of the main requirements in industrial biotechnology, a stable and markerless deletion of the genes responsible for the conversion of oAB towards tryptophan (*trpDC*) was used. Nevertheless, the oAB titer and yield reached with *P. putida* KT2440 are below those which are required to realize an industrial feasible process. Further improvement is required, e.g., by more in-depth metabolic engineering (e.g., overexpression of *tkt*: [@B7]) as well as by *in situ* product removal to alleviate product inhibition. Further research on the mechanism of product inhibition of oAB production could also lead to additional metabolic engineering targets to improve microbial oAB production.
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